E A Strobert
Overview
Explore the profile of E A Strobert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mathews D, Wakwe W, Kim S, Lowe M, Breeden C, Roberts M, et al.
Am J Transplant
. 2017 May;
17(9):2285-2299.
PMID: 28502128
Recently, newer therapies have been designed to more specifically target rejection in an effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific reagent, is associated with superior...
2.
Anderson D, Lo D, Leopardi F, Song M, Turgeon N, Strobert E, et al.
Am J Transplant
. 2015 Nov;
16(5):1456-64.
PMID: 26602755
Costimulation blockade with the fusion protein belatacept provides a desirable side effect profile and improvement in renal function compared with calcineurin inhibition in renal transplantation. This comes at the cost...
3.
Freitas A, Samy K, Farris A, Leopardi F, Song M, Stempora L, et al.
Am J Transplant
. 2015 Jul;
15(8):2240-9.
PMID: 26139552
Vascularized composite allografts (VCAs) are technically feasible. Similar to other organ transplants, VCAs are hampered by the toxicity and incomplete efficacy associated with conventional immunosuppression. Complications attributable to calcineurin inhibitors...
4.
Martin B, Samy K, Lowe M, Thompson P, Cano J, Farris A, et al.
Am J Transplant
. 2015 Feb;
15(5):1241-52.
PMID: 25702898
Islet xenotransplantation is a potential treatment for diabetes without the limitations of tissue availability. Although successful experimentally, early islet loss remains substantial and attributed to an instant blood-mediated inflammatory reaction...
5.
Lo D, Farris A, Song M, Leopardi F, Anderson D, Strobert E, et al.
Am J Transplant
. 2013 Oct;
13(12):3085-93.
PMID: 24119188
The integrin αvβ6 activates latent transforming growth factor-β (TGF-β) within the kidney and may be a target for the prevention of chronic allograft fibrosis after kidney transplantation. However, TGF-β also...
6.
Lo D, Anderson D, Weaver T, Leopardi F, Song M, Farris A, et al.
Am J Transplant
. 2013 Jan;
13(2):320-8.
PMID: 23311611
Belatacept is an inhibitor of CD28/B7 costimulation that is clinically indicated as a calcineurin inhibitor (CNI) alternative in combination with mycophenolate mofetil and steroids after renal transplantation. We sought to...
7.
Lowe M, Badell I, Turner A, Thompson P, Leopardi F, Strobert E, et al.
Am J Transplant
. 2013 Jan;
13(2):312-9.
PMID: 23279640
Calcineurin inhibitors (CNI) and steroids are known to promote insulin resistance, and their avoidance after islet transplantation is preferred from a metabolic standpoint. Belatacept, a B7-specific mediator of costimulation blockade...
8.
Page E, Page A, Kwun J, Gibby A, Leopardi F, Jenkins J, et al.
Am J Transplant
. 2012 Jul;
12(9):2395-405.
PMID: 22776408
Chronic allograft rejection is a major impediment to long-term transplant success. Humoral immune responses to alloantigens are a growing clinical problem in transplantation, with mounting evidence associating alloantibodies with the...
9.
Badell I, Russell M, Cardona K, Shaffer V, Turner A, Avila J, et al.
Am J Transplant
. 2012 Mar;
12(7):1918-23.
PMID: 22458552
Islet transplantation to treat type 1 diabetes has been limited in part by toxicities of current immunosuppression and recipient humoral sensitization. Blockade of the CD28/CD80/86 and CD40/CD154 pathways has shown...
10.
Badell I, Thompson P, Turner A, Russell M, Avila J, Cano J, et al.
Am J Transplant
. 2011 Sep;
12(1):126-35.
PMID: 21920020
Costimulation blockade of the CD40/CD154 pathway has been effective at preventing allograft rejection in numerous transplantation models. This strategy has largely depended on mAbs directed against CD154, limiting the potential...